Psoriasis drug achieves phase III endpoint

Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.

Related Videos
Related Content

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.